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Transcription can be controlled by regulating either the
initiation or elongation of RNA chains. Recent studies
highlight the importance of an elongation regulator,
Spt5, in controlling gene expression in yeast, fruit fly
and zebrafish; Spt5 may provide a link between
transcriptional elongation and cell fate.
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Eukaryotic messenger RNAs are synthesized by the
multisubunit enzyme RNA polymerase II, aided by myriad
cofactors that control different events in this multistep
process. A complete round of transcription involves: the
recruitment of polymerase and general transcription factors
to the promoter, RNA chain initiation and polymerase
escape from the promoter, RNA chain elongation, and
finally termination with release of polymerase and nascent
transcript from the DNA template [1]. Transcriptional elon-
gation is far less well understood than initiation, though pro-
teins have been identified that influence elongation in vivo
and in vitro. The general transcription factors TFIIF and
TFIIH stimulate both initiation and elongation. Other
factors are specific regulators of elongation, and these
include the polymerase II-associated protein TFIIS, modi-
fiers of chromatin structure and sequence-specific transacti-
vators such as HIV Tat [2,3]. A recent study [4] has now
identified a specific regulator of elongation, dubbed Foggy,
which appears to play an important role in the determina-
tion of cell fate.
A particularly fruitful line of investigation into transcript
elongation has concerned the mechanism of action of
the inhibitor 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole
(DRB). DRB was first discovered to have anti-viral effects
and was later shown to specifically inhibit elongation of
polymerase II transcripts, including those activated by the
HIV-1 Tat protein [5–8]. DRB is an ATP analogue that
inhibits a variety of protein kinases in vitro, but its in vivo
target remained elusive for more than three decades.
In vitro, DRB inhibits progress of polymerase II along a
template early in elongation, but not after the transcript is
more than 500 bases long [9]. Significant progress in under-
standing DRB function was made by Handa and colleagues
[10,11], who purified two factors from HeLa nuclear extracts
that are required for DRB to inhibit transcript elongation
in vitro. These factors were named DRB sensitivity induc-
ing factor (DSIF) and negative elongation factor (NELF). 
Human DSIF is a heterodimer of hSpt4 and hSpt5, so-
called because they are homologues of the budding yeast
proteins Spt4 and Spt5. The budding yeast SPT genes
were identified rather indirectly, by mutations that
restored expression of a gene that had been shut off by
nearby insertion of a Ty transposable element [12]. Spt5
binds to the large subunit of RNA polymerase II in vitro
[10,11,13,14], and has four ‘KOW’ homology domains.
Notably, KOW homology domains are also found in the
Escherichia coli RNA polymerase-binding protein NusG,
which affects transcriptional termination and anti-termina-
tion [15,16]. NELF has five subunits, including one called
RD which has a potential RNA-binding domain.
NELF and DSIF cooperatively repress elongation by
polymerase II. The two proteins co-immunoprecipitate
with unphosphorylated RNA polymerase IIA, but not
with the polymerase II0 isoform which is hyperphosphory-
lated on the carboxy-terminal domain (CTD) of the large
subunit. The CTD consists of repeated heptads with con-
sensus sequence YSPTSPS. Consistent with the binding
data, NELF and DSIF selectively inhibit elongation by
polymerase IIA — polymerase II0 is immune to their
negative effects [11]. Most polymerase II engaged on
template DNA in vivo is thought to be in the phosphory-
lated form. Phosphorylation of RNA polymerase II is very
complex, as each of the 52 heptads can potentially be
phosphorylated by several different kinases at either of
two different positions: serine residues 2 and 5. Whether
DSIF and NELF differentially affect the various different
phosphorylated forms of polymerase II remains to be
determined. 
Paradoxically, neither NELF nor DSIF has protein kinase
activity, so they are unlikely to be direct targets of DRB.
How, then, are NELF and DSIF involved in DRB-
mediated inhibition of elongation? The resolution of this
conundrum required identification of a third factor, the
‘positive transcription elongation factor b’ (P-TEFb), by
Price and colleagues (reviewed in [17]). P-TEFb was
isolated from Drosophila cells as an activity that stimulated
elongation of polymerase II transcripts. This factor turned
out to be a kinase complex composed of the cyclin-depen-
dent kinase Cdk9 and several alternative cyclin partners
— cyclin T1, T2 or K. P-TEFb hyperphosphorylates the
polymerase II CTD and is inhibited by low concentrations
of DRB. Both P-TEFb and Spt5 are required for HIV Tat
to stimulate elongation [14,17,18]. Tat binds to the cyclin
T subunit and drags its captive cellular kinase to viral
transcription complexes, where it hyperphosphorylates the
CTD to produce a supercharged polymerase for efficient
elongation of vir al RNAs (reviewed in [19]). DRB inhibits
the latter step and thereby prevents Tat from activating
transcription.
The connection between DRB and the negative or positive
elongation factors was made by Handa and colleagues
[11,20], who found that the only function of P-TEFb in a
transcription extract was to counteract the negative effects
of DSIF and NELF. When DSIF or NELF was depleted
from the extract, P-TEFb was no longer required for effi-
cient elongation. Conversely, depletion of P-TEFb inhib-
ited elongation and mimicked the effect of adding DRB
[20] (Figure 1). These studies show that the main mecha-
nism controlling polymerase II transcript elongation, in vitro
at least, is inhibition by DSIF and NELF, and that
P-TEFb counteracts these inhibitors by phosphorylating
the CTD of polymerase II and possibly also Spt5 [21].
DSIF is more than just a simple inhibitor of elongation;
rather, it appears to have a split personality. When ribonu-
cleoside triphosphate precursors are limiting, DSIF mani-
fests its positive qualities and actually enhances elongation
[10]. A third possible function of Spt5 is in the pre-mRNA
processing step that adds the 5′ cap to nascent transcripts
when they are about 25 bases long. The 7-methyl G 5′ppp5′
cap stabilizes mRNA and enhances translation; Spt5 binds
to, and stimulates, the guanylyltransferase that adds the
cap [22]. Interestingly, capping, like transcript elongation,
also requires polymerase II phosphorylation, as capping
enzymes must bind to the phosphorylated CTD in order
to find their substrate RNAs [23,24]. One interesting pos-
sibility suggested by these findings is that capping enzymes,
perhaps in association with Spt5, might influence poly-
merase II transcription.
The pioneering work on DSIF in vitro set the stage for
recent investigations that have addressed questions about
its role in vivo. How does this factor influence elongation
on a chromatin template, which is very different from the
naked DNA templates used in the in vitro studies? Is
DSIF an inhibitor or an enhancer of elongation in vivo, or
can it switch from one to the other? A positive role in elon-
gation is suggested by the finding that in budding yeast
the spt4 and spt5 mutants are hypersensitive to 6-azauracil,
a drug that reduces the concentration of ribonucleoside
triphosphates and is thought to inhibit elongation. Fur-
thermore, conditional mutations of SPT5 were found to be
suppressed by mutations in polymerase II [13].
On the polytene chromosomes of Drosophila salivary
glands, Spt5 and P-TEFb were found to co-localise at
many genes [25,26]. In chromatin immunoprecipitation
experiments, before transcription was activated by heat
shock, Spt5 co-localised with paused polymerase IIA at
the 5′ end of heat shock genes, consistent with a negative
role in elongation [26,27]. Surprisingly, after heat shock,
Spt5 was also found at the 3′ ends of activated heat shock
genes, along with P-TEFb. These findings raise the
question of whether Spt5 (DSIF) works in the same way
at the 5′ and 3′ ends of a gene? It seems unlikely that Spt5
acting at the 3′ end of an active heat-shock gene inhibits
elongation. Perhaps Spt5 inhibits elongation at 5′ end
prior to heat shock, and enhances elongation after heat
shock. If so, what could trigger  Spt5’s switch from being
an inhibitor to an enhancer of elongation? One possibility
is that changing the pattern of polymerase II CTD phos-
phorylation might be involved. In summary, the Drosophila
studies show that Spt5 and P-TEFb localise to the 5′ and
3′ ends of a specific subset of transcribed genes, but they
Dispatch R145
Figure 1
A model for the roles of the elongation
factors P-TEFb, DSIF (Spt4–Spt5) and
NELF in controlling transcription by RNA
polymerase II. Top: when DSIF/NELF interact
with unphosphorylated RNA polymerase II,
transcriptional elongation is inhibited [10,11].
DRB inhibits phosphorylation of the
carboxy-terminal domain (CTD) of the
polymerase large subunit by blocking the
P-TEFb (Cdk9—cyclin T) kinase. Bottom: a
gene actively transcribed by RNA polymerase
II, which is mostly phosphorylated on the
CTD [26]. Spt5 co-localizes with RNA
polymerase II at both 5′ and 3′ ends of the
gene. As polymerase travels along the gene
5′ to 3′ the state of CTD phosphorylation
(Ps) changes [23,24]. Whether DSIF
(Spt4–Spt5) activates or inhibits elongation
at the 5′ and 3′ ends of an actively
transcribed gene is not known. A is an
upstream transcriptional activator.
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do not unambiguously resolve whether Spt5 is working to
inhibit and/or enhance elongation.
Interesting insight into the physiological importance of
transcriptional regulation at the level of elongation has
come from the recent description of the first metazoan
SPT5 mutant [4]. The foggy mutant zebrafish was isolated
in a screen for defects in expression of tyrosine hydroxy-
lase, the enzyme that catalyses the rate-determining step
in biosynthesis of the catecholamines, dopamine, nora-
drenaline and adrenaline. The mutant embryos have a
normal gross anatomy, but die at day four of development
from circulatory problems. Their primary defect is loss of
catecholaminergic neurons in the peripheral and central
nervous system, including the hypothalamus and retina.
The foggy gene was cloned by complementation and found
to encode a 1084 residue protein with strong sequence
homology to Spt5. The foggy mutation results from substi-
tution of the evolutionarily invariant valine at position
1012 by aspartic acid. 
Guo et al. [4] showed that wild-type Foggy protein can
substitute for human Spt5 in conferring DRB inhibition of
elongation in HeLa transcription extract, but the V1012A
mutant form of Foggy does not. The mutant protein does,
however, retain the ability to stimulate elongation at low
nucleotide concentrations. These important results
suggest that Foggy/Spt5 function is required to downregu-
late an unknown target gene(s) during differentiation of
cells in the catecholaminergic neuron lineage. The fact
that the foggy mutant phenotype is restricted to a small
number of neurons may indicate that redundant gene
products can substitute for Foggy/Spt5 in other cell types.
The involvement of Foggy in neuronal differentiation
shows, for the first time, that negative regulation of
elongation serves an essential function in vivo.
The importance of negative regulators of elongation
comes as quite a surprise in light of the fact that, in vivo,
chromatin is thought to be a major obstacle to polymerase
movement. One might therefore have expected the primary
regulators in vivo to be enhancers of elongation rather than
inhibitors. Perhaps one lesson from this work is that
in vivo chromatin is modified so as not to be a major limit-
ing factor in transcript elongation. 
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